
Hemab Therapeutics is a privately held biotechnology company developing next‑generation prophylactic monoclonal and bispecific antibody therapies for serious bleeding and thrombosis disorders. The company aims to transform treatment paradigms for patients with unmet medical needs through a strong pipeline of innovative therapeutics.
Hemab Therapeutics is seeking a VP, Head of Global Regulatory Affairs to lead the company’s regulatory strategy and execution worldwide. This role involves partnering with R&D and CMC teams to ensure regulatory compliance and the successful development of next-generation prophylactic therapies. The company is focused on a pipeline of monoclonal and bispecific antibodies for rare bleeding disorders and has secured $55M in Series A funding.
Hemab Therapeutics is a privately held biotechnology company developing next‑generation prophylactic monoclonal and bispecific antibody therapies for serious bleeding and thrombosis disorders. The company aims to transform treatment paradigms for patients with unmet medical needs through a strong pipeline of innovative therapeutics.
Cytokinetics